Despite the availability of safe and effective hepatitis B virus (HBV) vaccines for more than 30 years, the burden of hepatitis B disease is still substantial. In 1992, the WHO recommended the inclusion of HBV vaccination in all national vaccination programmes. As of 2012, 47 of the 53 European countries (89%) had implemented a universal hepatitis B vaccination programme. The most recent countries to follow the recommendation were Ireland (in 2008) and the Netherlands (in 2011). Still, six countries (Denmark, Finland, Iceland, Norway, Sweden and the UK) adopt risk-group-targeted vaccination only, instead of adding a universal vaccination programme. However, changing demography, increasing immigration and the current vaccine costs make the cost-benefit ratios in these remaining low endemicity countries strongly in favour of universal HBV vaccination. Global efforts, including a cohesive European vaccination policy, are essential to control and prevent hepatitis B.
Hepatitis B is a prime target for prevention (and theoretically eradication) through vaccination, because it represents a serious public health threat, humans are the only known reservoir and safe and effective vaccines have been available for >30 years.
Still, the global burden of hepatitis B disease is substantial. About 2000 million people have been infected with hepatitis B virus (HBV) worldwide, 240 million people are chronically infected and between 500 000 and 700 000 people die annually as a result of HBV infection or its complications, such as liver cirrhosis and hepatocellular carcinoma [1] . In the European region of the WHO, the number of chronic carriers is estimated at 13 million, affecting 1 out of 50 people [2] . The highest hepatitis B surface antigen (HBsAg) prevalence rates in the general population are registered in Uzbekistan (13%) [2] . Although quality and standardized viral hepatitis surveillance data for Europe are still scarce, enhanced surveillance of hepatitis B across the countries in the European Economic Area during the past decade has highlighted the significant burden of the infection [3] . In 2011, over 17 000 newly identified cases of hepatitis B were reported from 28 European Economic Area countries.
Hepatitis B vaccine provides long-term protection (>20 years) against the infection and its consequences [4] . For population immunization, two strategies are used: universal vaccination and high-risk group targeting.
A variety of schedules may be used for universal hepatitis B immunization and different age groups can be targeted, depending on the local epidemiological situation and logistic considerations. Universal newborn or infant vaccination aims to address the people who would otherwise be infected perinatally or in early childhood, when the risk of chronic infection is highest: 90% of infants of HBsAg and hepatitis B e antigen (HBeAg)-positive mothers, infected during the first year of life, develop chronic infection, compared with 30% of children infected between 1 and 4 years of age and <5% of infected adults [5] .
In countries with high endemicity, administration of the first dose of HBV vaccine as soon as possible (<24 h) after birth is a critical step in preventing perinatal HBV transmission. The risk of HBV infection among infants born to HBsAg-positive mothers was found to be eight times higher when the birth dose was administered after 7 days from birth, compared with when it was administered within the first 3 days after birth [6] . In countries where mothers deliver in a healthcare setting, a high first-dose HBV vaccine coverage can be achieved when the vaccine is administered at birth, with the potential of increased compliance for subsequent doses. Indeed, studies in the USA indicate that children who received the first dose of hepatitis B vaccine during their first month of life (usually the birth dose) are more likely to complete the hepatitis B vaccine series as well as other immunizations [7, 8] . A birth dose of hepatitis B vaccination for all newborns also provides a safety net against gaps in maternal hepatitis B screening programmes and errors in reporting [8] .
However, the delivery of a birth dose places special demands on health systems to respond within 24 h of childbirth, and attitudes and practices of families and healthcare providers at the time of birth are often different to those relating to older infants [6] . Administering the first dose of HBV vaccine using combination vaccines at a later age (infant vaccination), can take advantage of the existing childhood immunization programmes, without requiring additional visits or injections and is therefore an economically attractive and effective way of achieving universal vaccination with high coverage [9] .
In countries with low endemicity, where hepatitis B infection is mainly acquired through risk behaviour by young adults, universal vaccination programmes (newborn/infant and/ or adolescents) aim to protect the entire population before they reach the age of greatest incidence of infection (adolescence and early adulthood). But in some low-prevalence countries, targeted risk-group vaccination is used as an alternative to universal immunization. Yet, high-risk programmes have several shortcomings and have so far failed to control viral hepatitis infection in the general population. The strategy requires all individuals in a high-risk group to have access to healthcare, be identified, and get vaccinated before they are infected. This is labour and cost intensive, at-risk groups are often hard to reach and the reported vaccine coverage achieved in the target populations has been too low to impact on the transmission of infection [10] [11] [12] [13] . Furthermore, in industrialized countries, about one-third of HBV infections occur in people with no known risk factor and are therefore missed by a high-risk approach [14] . Finally, targeting specific groups only wrongly suggests that hepatitis B is not a concern for the rest of the population [15] .
In 1992, the WHO recommended the inclusion of HBV vaccination in all national vaccination programmes. All infants should receive their first dose of hepatitis B vaccine as soon as possible after birth, preferably within 24 h [16] . As of 2012, hepatitis B vaccine was introduced in 181 countries (93%), reaching a global coverage with three doses of 79% compared with a coverage of 30% in 2000 [17, 18] .
Out of the 53 Member States of the European WHO Region, 47 (89%) introduced universal vaccination (Table 1) . A coverage of 90% or more for three doses of hepatitis B vaccine is achieved in most countries, with lower coverage rates registered in Ukraine (21%) and France (51%) ( Table 1 ) [19] . In 2012, 29 European countries targeted newborn babies, 15 targeted infants and three targeted older children or adolescents (Hungary, Slovenia and Switzerland). Some countries combine immunization of different age groups, at a national level, or in areas of high endemicity only (e.g. Russian Federation, Kazakhstan) ( Table 2 ) [20] [21] [22] [23] [24] . The data on the age groups covered by vaccination presented in Table 2 may underestimate the reality, because populations targeted by regional strategies or catch-up campaigns are not included. Indeed, catch-up programmes for older age groups have been or are still conducted in many countries [23, 24] . On the other hand, the age cohorts targeted by routine programmes might be incompletely vaccinated, because vaccination coverage varied over time, with low coverage rates reported especially in the first years after the introduction of the vaccine.
The first countries to implement universal hepatitis B vaccination in Europe were Cyprus in 1990, Bulgaria, Italy, Spain (autonomous region of Catalonia) and San Marino in 1991, and Israel in 1992 (Tables 1 and 2 ). Further progress was achieved over the years. The success of these routine childhood and adolescent immunization programmes in interrupting HBV transmission and the cost-effectiveness of the strategy, even in low prevalence countries, has been well demonstrated [25] [26] [27] [28] [29] .
The most recent European countries to introduce universal infant HBV vaccination were Ireland (2008) and the Netherlands (2011). An economic evaluation in Ireland in 2007 concluded that universal infant HBV vaccination was a cost-effective intervention compared with a selective vaccination policy, based on the use of a hexavalent vaccine [30] . As the disease burden of hepatitis B in the Netherlands did not decrease over the past 20 years and the targeted approach failed to reach a significant part of the risk groups, the Health Council of the Netherlands recommended universal infant immunization in 2010, considering that universal vaccination means better protection for high-risk groups as well as the whole population [31] . Still, by 2013, six European countries have not yet introduced universal immunization against hepatitis B: Denmark, Finland, Iceland, Norway, Sweden and the UK. They adopt risk-group-targeted vaccination, in addition to screening of pregnant women and immunization of neonates exposed to infection.
The Danish national guidelines for hepatitis B immunization were re-evaluated in 2005 to assess the possible need for universal childhood immunization, and the National Board of Health concluded that there were insufficient reasons to change their policy [32] . However, more recent assessments in the Northern European countries recommend considering universal infant vaccination because of the lack of effectiveness of at-risk vaccination in reducing the overall incidence of hepatitis B [15, 33, 34] and the cost-effectiveness of universal infant vaccination [35] . Several working groups in Norway are currently advocating routine HBV vaccination in their country, and a programme for routine vaccination of children has already been in place in at least one county (Norbotten) in Sweden since 2011 [36] .
Indeed, changing demography with increasing immigration and increased risk for HBV introduction from countries with intermediate and high endemicity makes the cost-benefit ratios in the remaining countries where endemicity is low and where there is no universal vaccination strongly in favour of universal HBV vaccination, in particular with the current vaccine costs. Given the high levels of immigration within the EU, the lack of uniformity in vaccination policies threatens the potential for EU-wide strategies to contain the spread of HBV [37] . Therefore, an expert group on hepatitis (within the European Parliament) recommended in 2007 to encourage a cohesive policy with universal immunization of all newborns/infants and/ or adolescents throughout Europe, as well as effective vaccination of populations at risk, in line with WHO recommendations [37] . WHO further strongly recommends that all regions and the associated countries develop time-bound realistic goals for hepatitis control and define specific process indicators, focusing on coverage of the birth dose and coverage of three doses of hepatitis B vaccine [16] . The WHO Regional Office for Europe should take the Western Pacific Region as an example, where a regional plan to control hepatitis through immunization was published in 2007 [38] . Irrespective of universal vaccination, programmes targeting behavioural high-risk groups are further needed until all countries have a generation of adolescents and young adults among whom transmission has been interrupted. In addition, for prevention through immunization, early diagnosis and effective treatment should be implemented, to contribute to reduction of transmission. Hepatitis B is a global public health problem, needing global efforts to control and prevent the disease.
